ROX Medical, Inc. Hires Dr. Sackner-Bernstein as CMO and Executive VP of Clinical and Regulatory Affairs

SAN CLEMENTE, Calif., /PRNewswire/ --Rox Medical Inc. (ROX), a privately held medical device company pioneering a minimally-invasive therapy for hypertension, today announced the appointment of Jonathan Sackner-Bernstein, MD as its Chief Medical Officer and Executive Vice President of Clinical and Regulatory Affairs.

Dr. Sackner-Bernstein brings experiences as engineer, cardiologist, clinical investigator, regulator and innovator to the ROX team. Following his academic career (primarily at Columbia University), Sackner-Bernstein shifted to developing his product development skills. He built and ran a Phase 1 clinical research unit, served in a senior role at the FDA, ran clinical/regulatory for a stem cell therapeutic and consulted for DARPA. Prior to joining ROX, Sackner-Bernstein served as consultant to a wide range of device, drug and biologic companies.

Dr. Sackner-Bernstein was recruited to the FDA’s Center for Devices as the number 2 in scientific/clinical matters. He led teams across a diverse portfolio – spanning from innovation programs to the post-market safety transformation. Sackner-Bernstein led several Center and Agency level interactions with other Federal Agencies and international regulatory authorities. Following separation from Federal service, Sackner-Bernstein was recruited by DARPA to support the launch of their new Biological Technologies Office.

“Dr. Sackner-Bernstein is a broadly experienced physician and seasoned medical device executive with clinical, FDA and medical device company background,” commented CEO Michael MacKinnon. “We are thrilled to have Dr. Sackner-Bernstein join the executive team at ROX Medical to progress this exciting technology to the market and potentially become the standard of care in hypertension.”

“The ROX Coupler represents a transformative opportunity in the treatment of hypertension,” explained Sackner-Bernstein. “As angioplasty forever altered the management of coronary disease, so I believe ROX has the opportunity to do for hypertension. Who wouldn’t want to join the team in such a pursuit?”

About ROX Medical, Inc.
ROX® Medical has developed an implantable device and therapy intended to treat uncontrolled high blood pressure. Blood pressure reduction is achieved by diverting a small amount of blood flow from the arterial system into the venous system. The ROX Coupler is a small stent-like device that is placed between the artery and vein located in the upper thigh. The Coupler is about the size of a dime and is easily placed using standard catheter techniques. ROX Medical is conducting the CONTROL HTN-2 clinical trial in the United States for hypertension (visit www.controlhtn2.com for more information). The ROX Medical Coupler is commercially available in Europe under CE mark.

View original content to download multimedia:http://www.prnewswire.com/news-releases/rox-medical-inc-hires-dr-sackner-bernstein-as-cmo-and-executive-vp-of-clinical-and-regulatory-affairs-300768472.html

SOURCE ROX Medical, Inc